Suppr超能文献

急性心肌梗死相关心源性休克中血管升压药和正性肌力药的系统评价与荟萃分析

Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.

作者信息

Karami Mina, Hemradj Veemal V, Ouweneel Dagmar M, den Uil Corstiaan A, Limpens Jacqueline, Otterspoor Luuk C, Vlaar Alexander P, Lagrand Wim K, Henriques José P S

机构信息

Heart Center, Department of Interventional Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Department of Cardiology, Isala, 8025 AB Zwolle, The Netherlands.

出版信息

J Clin Med. 2020 Jun 30;9(7):2051. doi: 10.3390/jcm9072051.

Abstract

Vasopressors and inotropes are routinely used in acute myocardial infarction (AMI) related cardiogenic shock (CS) to improve hemodynamics. We aimed to investigate the effect of routinely used vasopressor and inotropes on mortality in AMI related CS. A systematic search of MEDLINE, EMBASE and CENTRAL was performed up to 20 February 2019. Randomized and observational studies reporting mortality of AMI related CS patients were included. At least one group should have received the vasopressor/inotrope compared with a control group not exposed to the vasopressor/inotrope. Exclusion criteria were case reports, correspondence and studies including only post-cardiac surgery patients. In total, 19 studies (6 RCTs) were included, comprising 2478 CS patients. The overall quality of evidence was graded low. Treatment with adrenaline, noradrenaline, vasopressin, milrinone, levosimendan, dobutamine or dopamine was not associated with a difference in mortality between therapy and control group. We found a trend toward better outcome with levosimendan, compared with control (RR 0.69, 95% CI 0.47-1.00). In conclusion, we found insufficient evidence that routinely used vasopressors and inotropes are associated with reduced mortality in patients with AMI related CS. Considering the limited evidence, this study emphasizes the need for randomized trials with appropriate endpoints and methodology.

摘要

血管升压药和正性肌力药常用于急性心肌梗死(AMI)相关的心源性休克(CS)以改善血流动力学。我们旨在研究常规使用的血管升压药和正性肌力药对AMI相关CS患者死亡率的影响。截至2019年2月20日,我们对MEDLINE、EMBASE和CENTRAL进行了系统检索。纳入报告AMI相关CS患者死亡率的随机和观察性研究。与未使用血管升压药/正性肌力药的对照组相比,至少有一组应接受了血管升压药/正性肌力药治疗。排除标准为病例报告、通信以及仅纳入心脏手术后患者的研究。总共纳入了19项研究(6项随机对照试验),包括2478例CS患者。证据的总体质量等级为低。使用肾上腺素、去甲肾上腺素、血管加压素、米力农、左西孟旦、多巴酚丁胺或多巴胺治疗与治疗组和对照组之间的死亡率差异无关。与对照组相比,我们发现左西孟旦有改善预后向好的趋势(风险比0.69,95%置信区间0.47 - 1.00)。总之,我们发现没有足够的证据表明常规使用的血管升压药和正性肌力药与AMI相关CS患者死亡率降低有关。考虑到证据有限,本研究强调需要进行具有适当终点和方法的随机试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/622d/7408805/19afd4e31f3b/jcm-09-02051-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验